Byron Jones: h-index, Total Citations, and Citation Map
Byron Jones's h-index is 30 (73 i10-index, 7,114+ total citations across 1+ publications) according to Google Scholar as of May 2026. Byron Jones is affiliated with Novartis Pharma.
Byron Jones is a researcher affiliated with Novartis Pharma, specializing in biosimilars adaptive designs optimal design cross-over trials bioequivalence multicenter trials. Their work has been cited 7,114 times. This profile visualizes their global influence, highlighting strong citation networks in United States.
Byron Jones's Citation Metrics
Bibliometric impact based on 1 indexed publication.
- H-Index
- 30
- i10-Index
- 73
- Total Citations
- 7,114
- Citing Countries
- 1
As of May 2026.
Byron Jones has an h-index of 30 and 7,114 total citations across 1 publication, with research cited by institutions in 1 country.
Download Exports (PNG, CSV, Poster)
Free Viewing Byron Jones's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
We've mapped 5,000 of 7,114 citations for Byron Jones
We've shown the most-cited 5,000. Unlock the full crawl (7,113 more citations) to see every institution citing this scholar.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Top Cited Works
Tip: clickto hide a row from the map
Design and Analysis of Cross-Over Trials
20032,357
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
The researcher established a foundational framework for the design and analysis of cross-over trials, as evidenced by their seminal 2003 monograph.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
